MAIA Biotechnology, Inc. Common Stock (MAIA)

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits

MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the second quarter of 2024.

MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six patients continuing treatment beyond 12 months.

--News Direct--

MAIA Biotechnology's Unique Telomere Targeting Agent Currently In Clinical Development Shows Promise For The Multi-Billion Dollar Cancer Therapy Market

MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the first quarter of 2024.

MAIA stock results show that MAIA Biotechnology missed analyst estimates for earnings per share the fourth quarter of 2023.

--News Direct--

MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.

Vlad Vitoc, MD, MBA; CEO & Chairman of MAIA Biotechnology (NYSE: MAIA), was a guest on Benzinga’s All Access. MAIA is a targeted therapy immuno-oncology company focused on developing and commercializing drugs targeting cancers with novel mechanisms of action.

Shares of Wipro Limited (NYSE: WIT) rose sharply during Friday’s session after the company reported third-quarter financial results, issued guidance and declared an interim dividend. Wipro shares jumped 16.7% to $6.27 on Friday.

Shares of VCI Global Limited (NASDAQ: VCIG) fell sharply in pre-market trading after the company announced pricing of $2.75 million public offering. VCI Global shares tumbled 29.5% to $1.10 in pre-market trading Here are some other stocks moving in pre-market trading.

We're starting out the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!